TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3284690
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (prazosin 2 mg b.i.d. and verapamil 160 mg b.i.d.)
Study: 3284690
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug treatment (prazosin or verapamil)
Study: 29611086
Drug: Resveratrol (RSV)
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (RSV) 1g daily for 3 months with conventional treatment
Study: 29611086
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with regular treatment only
Study: 21934625
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg per day
Study: 11122840
Drug: Standard and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard and high-dose chemotherapy
Study: 7617628
Drug: Immunochemotherapy (Tactivin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunochemotherapy (Tactivin + antibacterial drugs)
Study: 7617628
Drug: Antibacterial drugs
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial drugs alone (Control)
Study: 2929485
Drug: Animal protein
Normalized name: Animal protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal protein (AP) diet with increasing vitamin B‐6 intake (0.5, 1.0, 1.5, and 2.0 mg/d) for 14‐21 d
Study: 2929485
Drug: Plant protein
Normalized name: Kindersprout Plant Protein Chocolate Shake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant protein (PP) diet with increasing vitamin B‐6 intake (0.5, 1.0, 1.5, and 2.0 mg/d) for 14‐21 d
Study: 323074
Drug: Lowest dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest dose of norgestrel-ethinyl estradiol (20 microng estrogen, 100 microng progestogen)
Study: 323074
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of norgestrel-ethinyl estradiol (20 microng estrogen, increased progestogen in 100-microng increments)
Study: 323074
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of norgestrel-ethinyl estradiol
Study: 31047803
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan at recommended doses for expansion (5.4 mg/kg or 6.4 mg/kg) administered intravenously once every 3 weeks.
Study: 31047803
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan at recommended doses for expansion (5.4 mg/kg or 6.4 mg/kg).
Study: 27364549
Drug: Carvedilol 10mg
Normalized name: Carvedilol 10mg Oral capsule, extended release
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol 10mg (dose-escalation)
Study: 27364549
Drug: Carvedilol 20mg
Normalized name: Carvedilol 20mg Oral capsule, extended release
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol 20mg (dose-escalation)
Study: 21700688
Drug: Oxygen inhalation
Normalized name: oxygen INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen inhalation in CMS patients
Study: 21700688
Drug: Oxygen inhalation
Normalized name: oxygen INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen inhalation in hypoxemic control subjects
Study: 21700688
Drug: Oxygen inhalation
Normalized name: oxygen INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen inhalation in normoxemic control subjects
Study: 21058471
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy group (acupuncture and mild moxibustion)
Study: 16338255
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose, then 75 mg/d) in addition to aspirin for up to 1 year
Study: 16338255
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in addition to aspirin for up to 1 year
Study: 11888520
Drug: L-arginine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (30 g for 1 h)
Study: 9489273
Drug: Repeated imaginal
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated imaginal reliving of trauma during exposure therapy
Study: 8919895
Drug: PCINA (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCINA (0.025 mg fentanyl over 6 min)
Study: 8919895
Drug: i.v.‐PCA (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v.‐PCA (0.025 mg fentanyl bolus, lockout interval 6 min)
Study: 1717669
Drug: Rhenium-186(Sn)HEDP, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhenium-186(Sn)HEDP, single intravenous administration of 30-35 mCi (1110-1295 MBq)
Study: 7118361
Drug: dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: dietary treatment
Study: 19786658
Drug: Lapatinib (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1,500 mg orally) plus letrozole (2.5 mg orally)
Study: 15550024
Drug: Aspirin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (75 mg day(-1))
Study: 15550024
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg day(-1))
Study: 11501686
Drug: Adapted preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted preventive intervention for families with parental depression; details on dosage and duration not available.
Study: 1626493
Drug: Digitalis (digoxin),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitalis (digoxin), specific dosage and duration not mentioned
Study: 10405943
Drug: Etidronate therapy
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etidronate therapy (400 mg for 14 days followed by 76 days of calcium carbonate 500 mg, repeated every 3 months)
Study: 10405943
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (500 to 1000 mg daily)
Study: 1877455
Drug: Cronassial (mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cronassial (mixed gangliosides), 40 mg daily intramuscular injection for 4 or 8 weeks
Study: 3906461
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 3-mg dose
Study: 3906461
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 5-mg dose
Study: 29924746
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training using traditional equipment and low-dose testosterone supplementation (ExT)
Study: 25092781
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) with standard chemotherapy (3 mg/m2/dose, administered once in induction course 1 and once in intensification course 2)
Study: 25092781
Drug: Standard five-course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard five-course chemotherapy alone
Study: 25092781
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) with standard chemotherapy
Study: 18699936
Drug: IVX-0142 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVX-0142 (80 mg)
Study: 16527229
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment according to the CAPT protocol
Study: 12953133
Drug: RIST (cladribine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIST (cladribine 0.11 mg/kg/day for 6 days, busulfan 4 mg/kg/day for 2 days, rabbit anti-thymocyte globulin 2.5 mg/kg/day for 2-4 days)
Study: 10761956
Drug: Self-selected aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-selected aspirin use for at least 180 days/year
Study: 10761956
Drug: Self-selected aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-selected aspirin use for 0 to 13 days/year
Study: 8622072
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further regional treatment
Study: 6386275
Drug: Clonidine 0.3
Normalized name: CLONIDINE 0.3MG/24HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.3 mg daily
Study: 6386275
Drug: Guanfacine 3
Normalized name: guanfacine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine 3 mg daily
Study: 19851298
Drug: Oral L-citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-citrulline (6 g/day)
Study: 10482210
Drug: Glucose (dextrose),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (dextrose), 60 g/d
Study: 8845475
Drug: Intramuscular granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular granisetron
Study: 1964663
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMW heparin) administered subcutaneously at a dose of 2 X 150 anti‐Xa units/kg body weight, n = 24
Study: 1964663
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin administered intravenously by continuous infusion at a dose of 450 anti‐Xa units/kg body weight daily for 10 days, n = 26
Study: 540524
Drug: Amoxapine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxapine (25 mg 3-times daily for 4 weeks)
Study: 540524
Drug: Imipramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (25 mg 3-times daily for 4 weeks)
Study: 12955426
Drug: Tirofiban therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban therapy in addition to aspirin and heparin therapy
Study: 10871828
Drug: Interferon-beta-1b (Betaferon)
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-beta-1b (Betaferon) 8 MIU subcutaneous every other day
Study: 10871828
Drug: Interferon-beta-1a (Rebif)
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-beta-1a (Rebif) 6 MIU subcutaneous once a week
Study: 9378843
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam 0.25 mg/kg
Study: 8402492
Drug: RG 12915
Normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG 12915 at 0.25 mg/kg
Study: 8402492
Drug: RG 12915
Normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG 12915 at 0.50 mg/kg
Study: 8402492
Drug: RG 12915
Normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG 12915 at 1.0 mg/kg
Study: 8402492
Drug: RG 12915
Normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG 12915 at 2.0 mg/kg
Study: 29024323
Drug: Oat bran
Normalized name: Oat bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran (60 g)
Study: 27302238
Drug: Intra-arterial treatment
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial treatment plus usual care
Study: 18427536
Drug: Halidor preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halidor preparation (100 mg, 3 times daily)
Study: 11331627
Drug: Low-dose exogenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose exogenous FSH (75 IU/day) started on cycle day 3
Study: 11331627
Drug: Low-dose exogenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose exogenous FSH (75 IU/day) started on cycle day 5
Study: 11331627
Drug: Low-dose exogenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose exogenous FSH (75 IU/day) started on cycle day 7
Study: 11331627
Drug: Low-dose exogenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose exogenous FSH (75 IU/day) for all groups
Study: 7515706
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg of magnesium sulfate intravenously before cardiopulmonary bypass (CPB)
Study: 7515706
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg of magnesium soon after CPB
Study: 7515706
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg of magnesium before and after CPB
Study: 31318225
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement cognitive-behavioral treatment (MET-CBT)
Study: 27552564
Drug: (-)-epicatechin (EPI)
Normalized name: epicatechin
DrugBank: Epicatechin (DB12039)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (-)-epicatechin (EPI) at a total daily dose of 100mg
Study: 14524058
Drug: Antithrombotic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic treatments (various types).
Study: 1569294
Drug: Methionyl growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionyl growth hormone (met‐GH) infusion (160 ng/kg/min lasting 180 min)
Study: 1569294
Drug: Acipimox sustained
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox sustained release (ACX-SR) administered at 21:30 h and 09:30 h
Study: 2866257
Drug: Astemizole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole (10 mg t.i.d. on day 1, 10 mg b.i.d. on day 2, 10 mg o.d. for the remainder of the study)
Study: 31634003
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of Hyaluronic Acid (HA) 1 week before the marathon
Study: 24828079
Drug: Citalopram (antidepressant,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (antidepressant, selective serotonin reuptake inhibitor)
Study: 22723318
Drug: AZD6370 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6370 (300 mg)
Study: 22723318
Drug: AZD1656 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1656 (80 mg) plus insulin (1 mU/kg · min)
Study: 22723318
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (0.8 mU/kg · min)
Study: 22723318
Drug: Insulin alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin alone (1 mU/kg · min)
Study: 15380907
Drug: 250 kcal,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 kcal, 20 g protein supplement
Study: 15380907
Drug: 250 kcal,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 kcal, 3.5 g protein supplement
Study: 11472706
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg daily for 12 weeks
Study: 11472706
Drug: Niacin 3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin 3,000 mg daily for 12 weeks
Study: 7851059
Drug: Complete bed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete bed rest for 10 hours after ingestion of the maintenance dose of digoxin
Study: 3132910
Drug: Two-day cathartic/enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-day cathartic/enema preparation with oral administration of erythromycin and neomycin
Study: 3132910
Drug: Orthograde lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthograde lavage preparation with oral administration of metronidazole and neomycin
Study: 29529614
Drug: preopPTEd (one‐on‐one
Approvals — FDA: no, EMA: no, PMDA: no
Description: preopPTEd (one‐on‐one preoperative physical therapy education session and access to a web‐based microsite)
Study: 24158878
Drug: Carbetocin 20-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin 20-100 μg iv
Study: 18520295
Drug: Vandetinib (ZD6474)
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vandetinib (ZD6474) at a dose of up to 300 mg once daily
Study: 18520295
Drug: Vandetinib administered
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vandetinib administered concurrently with chemotherapy
Study: 15808378
Drug: Vaginal insert
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal insert (10 mg over 12 h)
Study: 15808378
Drug: Cervical gel
Normalized name: ENDOCERVICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical gel (0.5 mg, twice in 12 h)
Study: 10522767
Drug: Nursing intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nursing intervention using Orem's self‐care theory, five 30‐min sessions once a week during treatment and two follow-up sessions after treatment.
Study: 8527016
Drug: Paediatric ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Paediatric ibuprofen
Study: 7017017
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of doxycycline per dose, taken biweekly for three weeks
Study: 7017017
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of doxycycline per dose
Study: 27852695
Drug: Methotrexate +
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate + Infliximab (M+I) (5 mg/kg)
Study: 27852695
Drug: Infliximab therapy
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab therapy (after 54 weeks)
Study: 26399192
Drug: Constraint-Induced Aphasia
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-Induced Aphasia Therapy (CIAT), 4 hours/day for 10 consecutive business days (total 40 hours)
Study: 23422107
Drug: rhPTH (1-34)
Normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhPTH (1-34) 20 µg daily for 18 months
Study: 23422107
Drug: elcatonin 20
Normalized name: melatonin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: elcatonin 20 U weekly for 12 months
Study: 14749206
Drug: Rosiglitazone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (8 mg/day for 24 weeks)
Study: 8091041
Drug: Alternative treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatments for rheumatoid arthritis
Study: 21355716
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) Regular Human Insulin (RHI)
Study: 21355716
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) Insulin Lispro (IL)
Study: 21355716
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) Insulin Lispro (IL) and Regular Human Insulin (RHI)
Study: 20690287
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of teacher instruction and peer education (E3)
Study: 510179
Drug: Ethanol, 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol, 0.8 ml/kg
Study: 25735992
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg JNJ-40411813
Study: 25735992
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg JNJ-40411813
Study: 25735992
Drug: 150-225 mg
Normalized name: aminophylline 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150-225 mg JNJ-40411813
Study: 25735992
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg JNJ-40411813
Study: 22290001
Drug: 200 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 µg NTG plus 3 mg/kg 2% lidocaine
Study: 22290001
Drug: 300 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 µg NTG plus 3 mg/kg 2% lidocaine
Study: 22290001
Drug: 400 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 µg NTG plus 3 mg/kg 2% lidocaine
Study: 22290001
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg 2% lidocaine diluted with saline (Control Group LS)
Study: 19653788
Drug: Medication Contingencies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Contingencies (MC)
Study: 16409324
Drug: Aqueous 17%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous 17% (w/v) ethylenediaminetetraacetic acid rinse for 2 or 10 min followed by a 2% Patent Blue dye solution for 2 or 10 min
Study: 16409324
Drug: Tap water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tap water rinse for 2 or 10 min followed by a 2% Patent Blue dye solution for 2 or 10 min
Study: 11423841
Drug: Topical 20%
Normalized name: urea topical 20% topical foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 20% aminolevulinic acid hydrochloride (ALA) with optimal light dose of 10 J/cm²
Study: 11423841
Drug: Vehicle treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle treatment with light
Study: 3318751
Drug: Corticosteroid tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroid tapering regimen of one week
Study: 3318751
Drug: Corticosteroid tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroid tapering regimen of seven weeks